Peer review and it’s role in the NIH funding process is frequently the subject of policy commentary, but infrequently subject to change. In The Kill Zone, @cdbrose makes some points about defence that also apply to research
https://t.co/d30GRO5SJW
@whereisdaz The marketing spin is a commercialisable asset and can be delinked from the substantive underlying research. And we now live in a world where people will pay for a jpeg on blockchain. Just saying...
OpenAlex is live!
Docs are up, API is running, snapshots are available -- dig in and let us know what you think!
Sampler:
Docs: https://t.co/dRneP0MtkX
API: https://t.co/D7EFnw61P2
Display: https://t.co/NIzTzTTukw
Feeling lucky? https://t.co/xymQPWzLvF
Thread for highlights!
@jenheemstra Have you read Apprentice to Genius? It tells the story of the culture at the Johns Hopkins labs since ww2. It goes deep into your point here and offers an insight into what makes a good research mentor, especially in contrast to the normalisation of everyone taking a phd
In December 2020, we noticed a few findings — some of them from Fast Grants-funded scientists — that led us to be optimistic that fluvoxamine might be an effective Covid-19 treatment.
Australia's new Foreign Arrangement Scheme empowers the Foreign Affairs Minister to veto research partnerships (existing and prospective) involving foreign universities or partners that lack "institutional autonomy".
https://t.co/ajyZcCgYUt
While it's remarkable that Australia acted before the UK/US, perhaps signalling the degree of concern around BRI.
For now, these rules appear to have created a whole lot of admin (and the threat of admin) with little guidance on how they will be applied.